-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-06-26
BLCO:NYE- (USD)
COMMON STOCK | Medical Instruments & Supplies |
Last Closing
USD 14.77Change
-0.12 (-0.81)%Market Cap
USD 5.25BVolume
0.26MVerdict
Verdict
Values as of: 2024-06-26
COMMON STOCK | Medical Instruments & Supplies |
Last Closing
USD 14.77Change
-0.12 (-0.81)%Market Cap
USD 5.25BVolume
0.26MVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
BDX | Becton Dickinson and Company |
+2.77 (+1.20%) |
USD 68.18B |
ALC | Alcon AG |
-0.63 (-0.70%) |
USD 44.25B |
HYB | New America High Income Closed.. |
+0.05 (+0.69%) |
USD 35.93B |
RMD | ResMed Inc |
-0.16 (-0.08%) |
USD 30.24B |
WST | West Pharmaceutical Services I.. |
+0.63 (+0.19%) |
USD 24.60B |
BAX | Baxter International Inc |
-0.07 (-0.21%) |
USD 17.42B |
ATR | AptarGroup Inc |
-3.06 (-2.13%) |
USD 9.72B |
TFX | Teleflex Incorporated |
+3.10 (+1.50%) |
USD 9.36B |
XRAY | Dentsply Sirona Inc |
-0.38 (-1.50%) |
USD 5.33B |
STVN | Stevanato Group SpA |
-0.39 (-2.08%) |
USD 4.78B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
FSYD | Fidelity Sustainable High.. | 0.00 % | 0.00 % |
-0.07 (-0.14%) |
USD 0.02B |
Market Performance vs. Industry/Classification (Medical Instruments & Supplies) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | -13.42% | 32% | F | 14% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -13.42% | 32% | F | 13% | F | ||
Trailing 12 Months | |||||||
Capital Gain | -23.71% | 37% | F | 10% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -23.71% | 32% | F | 10% | F | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 1.61% | 42% | F | 48% | F | ||
Dividend Return | 1.61% | 37% | F | 37% | F | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 11.84% | 95% | A | 73% | C | ||
Risk Adjusted Return | 13.63% | 42% | F | 38% | F | ||
Market Capitalization | 5.25B | 58% | F | 77% | C+ |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
The company had positive total free cash flow in the most recent four quarters.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company had negative total cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median revenue growth in the previous 5 years compared to its sector